logo-loader
RNS
Apollon Formularies PLC

Apollon Formularies - Apollon CEO Keynote speaker at Cannabis Conference

RNS Number : 1912Y
Apollon Formularies plc
05 September 2022
 

5 September 2022

Apollon Formularies Plc

Chairman and CEO of Apollon is a Keynote speaker at the Cannabis Science Conference in Baltimore

Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK-based international pharmaceutical company trading on the Aquis Stock Exchange, is pleased to announce that Dr. Stephen Barnhill, Chairman and CEO of Apollon, is an invited keynote speaker at the Cannabis Science Conference ("CSC"), being held in Baltimore on 14-16 September 2022. Dr. Barnhill will deliver a presentation on the "Unique Combination of Cannabis and Mushrooms for the Treatment of Cancer" at 3:40 pm EDT/20:40 pm BST on 15 September.

CSC is the world's largest and fastest growing cannabis science event with a specialised focus on medical cannabis, analytical science, cultivation science, psychedelic science, hemp, and CBD. The conferences bring together a wide range of experts within the cannabis industry, including research scientists, medical practitioners, policy makers, instrument manufacturers and testing labs. The event aims to improve cannabis science and education. No new information related to Apollon will be released during the session.

Stephen Barnhill, MD, Chairman and CEO of Apollon Formularies plc, stated: "I am honoured to have been invited to address the upcoming Cannabis Science Conference, a world-leading medical cannabis event. It will serve as an opportunity to showcase Apollon's compelling third-party testing results which showed its proprietary medical cannabis formulations successfully killing nearly 100% of prostate, triple negative and HER2+ breast cancer cells in 3D cell cultures. This endorsement by CSC is significant for Apollon, as it further strengthens our credibility and will improve our visibility, particularly in North America."

Interested parties can register for the event via the website: www.cannabisscienceconference.com

- Ends -

For additional information, please visit www.apollon.org.uk or contact:

Apollon Formularies                                                     

Tel:                                                      +44 771 198 0221

Stene Jacobs                                      stene@apollon.org.uk 

 

BlytheRay (Financial PR/IR-London)                 

Tel:                                                       +44 207 138 3204

Tim Blythe/Megan Ray                      apollon@blytheray.com

About Apollon Formularies and Apollon Formularies Jamaica

Apollon Formularies plc is an international medical cannabis and medicinal mushroom pharmaceutical company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate (R&D), perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRALIMMTMTJMTLT
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read